{"id":117,"date":"2025-01-14T10:00:00","date_gmt":"2025-01-14T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=117"},"modified":"2025-09-01T09:19:04","modified_gmt":"2025-09-01T09:19:04","slug":"china-bd-2025-simcere-zaiming-and-abbvie-enters-a-1-billion-license-on-cfbi-gprc5d-bcma-cd3-tsabs-sim0500","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/117.html","title":{"rendered":"[China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D\/BCMA\/CD3 TsAbs SIM0500"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-01-13 (January 13, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: SIM0500<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Simcere Zaiming (a subsidiary of Simcere Pharmaceutical Group Ltd\uff0cChina)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): AbbVie Inc.\uff08US\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: TsAbs (humanized trispecific antibody)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: GPRC5D, BCMA, and CD3,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: Multiple Myeloma<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase 1 , in both\u00a0China\u00a0and the U.S.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority: Co-development, an option to license<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment and milestone payments up to \u00a0$1.055 billion, <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tiered royalties on net sales outside of the\u00a0Greater China\u00a0territory. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/news.abbvie.com\/2025-01-13-AbbVie-and-Simcere-Zaiming-Announce-Partnership-to-Develop-a-Novel-Trispecific-Antibody-Candidate-in-Multiple-Myeloma\">https:\/\/news.abbvie.com\/2025-01-13-AbbVie-and-Simcere-Zaiming-Announce-Partnership-to-Develop-a-Novel-Trispecific-Antibody-Candidate-in-Multiple-Myeloma<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-01-13 (January 13, 2025) Asset Name: SIM0500 Licensor: Simcere Zaiming (a subsidiary of Simcere &hellip; <a title=\"[China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D\/BCMA\/CD3 TsAbs SIM0500\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/117.html\"><span class=\"screen-reader-text\">[China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D\/BCMA\/CD3 TsAbs SIM0500<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-117","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=117"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/117\/revisions"}],"predecessor-version":[{"id":118,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/117\/revisions\/118"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}